Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Differential Humoral Response Of Genotype 1b Hepatitis C Virus F Protein Between Chronic And Recovered Infections

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

Characterization of the Specific CD4+ T Cell Response Against the F Protein During Chronic Hepatitis C Virus Infection.

[Detection of Serum Anti-F Antibody in Hepatitis C Virus Infected Patients].

Complementarity-Determining Region 3 Size Spectratypes of T Cell Receptor Β Chains in CD8 + T Cells Following Antiviral Treatment of Chronic Hepatitis B

Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.

Immunoglobulin M Antibody Response to Hepatitis C Virus Core Protein in Patients with Chronic Hepatitis C.

Expression of Hepatitis C Virus Hypervariable Region 1 and Its Clinical Significance

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Retrospective analysis of non-A-E hepatitis: possible role of hepatitis B and C virus infection.

Determination of the Human Antibody Response to the Neutralization Epitopes Encompassing Amino Acids 313-327 and 432-443 of Hepatitis C Virus E1e2 Glycoproteins

CHANGES OF ANTIBODIES AGAINST ANTIGENS ENCODED BY DIFFERENT REGIONS OF HCV GENOME IN CHRONIC HEPATITIS C PATIENTS TREATED WITH INTERFERON

Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.

Comparative study on immunological memory of CD8~+ T lymphocytes responses to different stages of chronic hepatitis B

Immune Response to a Hepatitis C Virus Nonstructural Protein in Chronic Hepatitis C Virus Infection.

Autoantibodies and Anti-Interferon Antibody in Patients with Chronic Viral Hepatitis and Its Clinical Significance: a Preliminary Investigation.

Expression and Purification of the Fusion Hepatitis C Virus Hypervariable Region 1 Protein and It's Preliminary Application

A Higher Correlation Of Hcv Core Antigen With Cd4+T Cell Counts Compared With Hcv Rna In Hcv/Hiv-1 Coinfected Patients